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1. Introduction
Malignant melanoma is a tumor that originates from the melanocytes and manifests mainly
on the skin. Melanomas are usually strongly pigmented, however amelanotic forms have been
observed. Relative to the tumor mass, melanomas have an early tendency to metastasize; the
prognosis is therefore poor. Malignant melanoma is responsible for about 90% of skin cancer
related mortality [1]. Several risk factors for the development of melanoma have been identi‐
fied. Ethnic origin is particularly important with a disease that mostly affects people of
European origin. Epidemiological studies have shown that exposure to the sun, especially in
childhood, is a major environmental cause of melanoma, and that up to 65% of the cases of
melanoma are frequently related to sunburn [2,3].
While it is easy for cancer prevention, the incidence of melanoma has increased dramatically
over the last four decades and melanoma is now one of the most common forms of cancer,
with significant morbidity and high mortality due to its propensity to metastasize. It has a high
propensity for haematogenous and lymphatic dissemination to regional and distant sites and
is poorly responsive to most systemic therapies. The 5-year survival rate for metastatic
melanoma is dismal, ranging from 5% to 10% with a median survival of less than eight months
with treatment [4,5].
The therapies used in advanced cases, such as chemotherapy, radiotherapy, biochemotherapy
and vaccine, seem unable to provide a cure or improved survival of becoming a melanoma
tumors most refractory to treatment [6,7]. Although surgery and radiation therapy are very
important in the treatment of metastatic disease, systemic treatment remains the basis of
© 2013 Locatelli et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
therapy for the majority of patients, including chemotherapy, immunotherapy, or a combina‐
tion of approaches such as biochemotherapy [8]. Many compounds have been investigated for
antitumor activity in melanoma, but the current treatment options for patients with metastatic
disease are limited and non-curative in the majority of cases.
Chemotherapy with cytotoxic agents has been used for the treatment of metastatic melanoma
for over three decades. Among the antitumoral agents, efficacy is modest in metastatic
melanoma including alkylating agents (dacarbazine, temozolomide, nitrosoureas), analogues
of platinum (cisplatin, carboplatin) and microtubular toxins (vincas and taxanes), which have
been used alone or in combination [8]. Specifically in relation to cytotoxic chemotherapy,
dacarbazine used as a chemotherapeutic agent still represents the single most common option
[8]. It was demonstrated that combinations of cytotoxic agents can produce low response rates,
although higher than monotherapy with dacarbazine, which are associated with increased
toxicity and do not extend significantly the survival of patients [8]. Although of limited
therapeutic effect, dacarbazine cannot be dismissed as standard therapy for disseminated
melanoma, as in evidence-based analysis no other regimen had greater benefits for the patients’
survival [9]. By 2011, only two drugs for metastatic melanoma therapy had been approved by
the Food and Drug Administration (FDA), which were dacarbazine and a high dose of
interleukin 2 (IL-2). In 2011, the FDA approval of vermurafenib (chemotherapy agent) and
ipilimumab (monoclonal antibody) for clinical studies raised optimism for the treatment of
metastatic melanoma, since the therapies used until then had had serious limitations, and thus
the use of novel strategies for melanoma treatment seemed promising. However, the use of
these drugs is limited [10]. The strategies to increase the responsiveness of new therapies are
the association with other drugs currently in clinical use, such as dacarbazine, although these
therapies are under investigation in vitro and in vivo models.
Other new chemotherapies, including drugs that target biological receptors, are currently in
development. Among these are bevacizumab, an endothelial growth factor antibody, and
sorafenib, a cellular pathway inhibitor [11]. These agents have shown some efficacy in early
clinical trials. The lenalidomide is a thalidomide derivative designed to be more effective and
less toxic [12]. In a phase I trial, it was found to be well tolerated by patients with metastatic
melanoma and to produce immune activation. Another agent of interest that has shown
promising results are the anti Bcl-2 antisense (oblimersen), tested in metastatic melanoma. A
combination of Bcl-2 antisense and dacarbazine showed better response than dacarbazine
alone, although no significant improvement in overall survival was observed [13,14].
Several clinical trials are being carried out to investigate the antitumor efficacy of new agents
as well as diverse immunosuppressive therapeutic strategies, including the use of dendritic
cells, high-doses of interferon-α (IFN-α) and/or IL-2 and anti-cytotoxic T lymphocyte-associ‐
ated antigen 4 (CTLA-4) antibody, alone or in combination with current therapies for treating
locally advanced, metastatic and recurrent melanomas [15].
Significant advancements made in the last few years have provided important information on
the molecular signalling pathways and gene products, which are frequently deregulated in
melanoma stem/progenitor cells and their progenies during melanoma formation and
progression to locally advanced and metastatic disease states. Consequently, the combination
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of different molecular biomarkers or cytotoxic agents targeting distinct gene products altered
during melanoma development may constitute more promising therapeutic strategies. Several
other signal transduction pathways have been found to be constitutively active or mutated in
other subsets of melanoma tumors that are potentially targetable with new agents. Among
these, NF-kB is another pathway that melanoma tumors use to achieve survival, proliferation,
resistance to apoptosis and metastasis. In fact, it has been demonstrated that up regulation of
the NF-kB levels is involved in both the progression of melanoma and an increase of its
metastatic potential. Therefore, inhibition of NF-kB activation seems to be a promising target
for anti-cancer therapies [16,17].
Recent studies have shown that proteasome inhibitors such as bortezomib represent a new
class of anticancer agents by degradation inhibition of cell cycle regulatory proteins, such as
cyclin-dependent kinase inhibitors and I-kB protein. The efficacy of bortezomib was recently
explored in another 2-stage phase 2 clinical trials in combination with other chemotherapeutic
agents, including paclitaxel and carboplatin, in patients with advanced solid tumors. The
results from these studies evidenced narrow clinical benefit and significant toxicity, hindrances
that limit the use of bortezomib [18].
Another compound known to exert numerous pharmacological properties - mostly antioxi‐
dant, anti-inflammatory and antiproliferative - is curcumin, a polyphenol present in in
Curcuma longa, a species belonging to the ginger family (Zingiberaceae). With regard to
antiproliferative activity, it showed pro-apoptotic activity in a variety of tumors in vitro. To
achieve these results, curcumin was used in experiments based on melanoma either in vitro
or in vivo models. The importance of curcumin also lies in the fact that this drug seems to
reduce the metastatic potential of melanoma, which is the main cause of death [19].
Understanding and overcoming resistance pathways by combining current and future agents,
identifying biomarkers to improve therapy and discover new therapeutic targets are promis‐
ing advances in the treatment of melanoma. In light of this, the purpose of this chapter is to
summarize the recent advances in the treatment of metastatic melanoma and to describe the
current limitations, as well as to comment on promising future strategies to overcome the
limitations.
2. Single agent chemotherapy
Melanoma is considered a chemotherapy-resistant tumor, but in fact several chemotherapeutic
agents show single-agent activity at the level of 10% to 15%, similar to the efficacy of the
chemotherapeutic armamentarium used against other tumor types. Several combination
chemotherapy regimens have been tested, but no survival benefit has been demonstrated. Few
of these trials have been compared with standard dacarbazine (DTIC) in an adequately
powered randomized trial, and even the most extensive of these trials only aimed to detect
unrealistically large improvements in overall survival [20]. For the systemic monotherapy of
advanced melanoma, several substances are available whose clinical efficacy is comparable.
Palliative monochemotherapy can shrink tumors and thus achieve a reduction in tumor-
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related symptoms. The more active agents are the alkylants (dacarbazine, temozolomide,
fotemustine, carmustine, semustine), platinum drugs (cisplatin and carboplatin), vinca
alkaloids (vindezine and vinblastine), taxanes (docetaxel and paclitaxel), and tamoxifen [7,21].
Table 1 shows the drugs and dosages for monotherapy to melanoma.
Drugs Dosage Overall response
Dacarbazine 250 mg/m2/day for 5 days every 3-4 weeks 5.3 – 25%
Temozolomide 150-200 mg/m2/day for 5 days every 4 weeks 13.5-21%
Carmustine 75-110 mg/m2 13-18%
Semustine 130 mg/m2 16%
Fotemustine 100 mg/m2/day every 3 weeks 7.4-25%
Cisplatin 60-150 mg/m2 15%
Carboplatin 400 mg/m2 every 4 weeks 19%
Vindezine 3 mg/m2 every 14 days 12-26%
Vinblastine 6-8 mg/m2 every 1 week 13%
Docetaxel 100 mg/m2 every 21 days 14%
Paclitaxel 125-275 mg/m2 15%
Tamoxifen 20 mg/day 4-13%
Interferon α 9m-18m IU/m2 3x/week continuous administration 13-25%
Interleukin-2 600 000 IU/Kg as 15 minute short infusion i.v. every 8 hours on days 1-5
(maximum 14 individual doses) repeat cycle day 14
16-21.6%
Adapted by Garbe et al. (2008) [21] and Mouawad et al. (2010) [7].
Table 1. Single drugs, dosage and their activity in melanoma.
2.1. Alkylants agents
2.1.1. Triazenes
The  alkylating  agent  dacarbazine  (DTIC,  dimethyltriazeno  imidazole  carboxamide)  was
first introduced some 30 years ago, and it is considered to be the reference of single agent
for the management of advanced melanoma. This compound was initially designed as an
antimetabolite because it is an analogue of 5-aminoimidazole-4-carboxamide, an intermedi‐
ate  in  purine  biosynthesis.  However,  it  presented  cytotoxicity  that  is  related  to  the
generation  of  methyldiazonium,  which  methylates  DNA  during  its  metabolism  [22].
Methyldiazonium has a half-life of about 0.4 s in aqueous solution, sufficient time to allow
it  to  reach  its  target.  In  1975  this  carboxamide  was  approved  by  the  Food  and  Drug
Administration (FDA), and has since been considered the standard of metastatic melano‐
ma care. Single-agent DTIC has remained the standard of care for 3 decades, with response
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rates of 8% to 20% and mean duration of response of approximately four to six months.
Several studies of dacarbazine in the management of metastatic melanoma were publish‐
ed in the early 1970s [23,24]. The first of these trials demonstrated a 19% response rate in
110 evaluable patients who received dacarbazine in 3-weekly cycles, most frequently at a
dose of 250 mg/m2  daily for five days [25].  A second study showed an overall  response
rate of 28% in 115 evaluable patients receiving dacarbazine 2.5 or 4.5 mg/kg daily for ten
days  of  a  thirty-day  cycle,  and  another  showed  response  rates  approaching  20%  with
dacarbazine 150 mg/m2  daily for five days of a thirty-day cycle in 112 evaluable patients
[24]. The typical dacarbazine dose is 850 to 1,000 mg/m2 every three weeks [26].
Among the randomized trials in which dacarbazine was used as a comparator arm, the patients
treated with dacarbazine with an overall response rate of 13.4% and median survivals ranging
from about six months to eleven months. Given the low response rate, it is unrealistic to expect
dacarbazine to have an effect on median survival [27].
Studies suggest that less than 5% of patients achieve a complete response to therapies with
dacarbazine alone or in combination, and less than 2% of patients survive five years more. The
majority of previous reports suggest that long-term survival is restricted to patients with
favourable clinical features, such as nodal, cutaneous or pulmonary metastasis [28].
Although dacarbazine presents a relatively small therapeutic response, it is still considered
the standard drug for the treatment of melanoma, whereas the drug combination and the use
of other drugs do not show effect as monotherapy.
Another problem with associated dacarbazine is the high toxicity. The major toxic effects
associated with dacarbazine are the development of neutropenia, thrombocytopenia, alopecia,
nausea or vomiting, fatigue and liver damage [29].
Besides its toxicity, dacarbazine has several drawbacks because of its hydrophilicity, which
leads to slow and incomplete oral absorption, and therefore the alternative is intravenous
administration. Another disadvantage is its high photosensitivity, with a very short half-life
(about 30 min), decomposing to 2-azah hypoxanthine via an intermediate diazonium species.
For this reason, intravenous infusion bags of dacarbazine must be protected from light. These
problems have stimulated the synthesis of dacarbazine analogues, the most important of which
is temozolomide [20].
Temozolomide is an oral alkylated compound similar to dacarbazine (the most active single
agent in primary melanoma), which has 100% of oral bioavailability and considerable pene‐
tration in Central Nervous System tissue, mainly due to its lipophilic character [30]. Moreover,
for its acid-stability the molecule remains in cerebro-spinal fluid, where it reaches 30–40% of
plasmatic concentration [31]. For this reason, differently from dacarbazine, temozolomide is
employed in the treatment of primitive [32] and metastatic brain tumors [31]. Although the
FDA has not approved it for melanoma, temozolomide is widely used and has response rates
similar to dacarbazine in melanoma [26,33].
Despite the absence of approval, temozolomide is also used ‘‘off-label’’ in patients with
malignant melanoma after standard treatment. Temozolomide has been proven to have an
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equal efficacy (with a 10–20% response rate) to that of dacarbazine, the most commonly used
chemotherapy agent in metastatic melanoma, in a randomized phase III trial [34,35]. However,
TMZ administered in monotherapy did not show significant improvement in the overall
response rate or median survival time. Nonetheless, the works of Biswas et al. (2006) [36],
Chang et al. (2007) [37], Platta et al. (2007) [38] and Mehta et al. (2010) [39] show the efficacy
and modest side effects of single-agent TMZ in patients with recurrent or progressive brain
metastases.
In a randomized trial comparing temozolomide given for five days every month with dacar‐
bazine given once every 3 weeks, there was no difference in response rate or survival [26].
Despite this, temozolomide offers two potential advantages over dacarbazine. Temozolomide
readily crosses the intact blood-brain barrier, which provides enhanced activity against brain
metastases. Unfortunately, the objective response rate of melanoma brain metastases to
temozolomide is low [37], although there is some indication that treatment with temozolomide
is associated with a lower incidence of disease progression in the brain [38,39]. Another
potential advantage of temozolomide is that, as an oral agent, continuous dosing is feasible.
An extended-dosing schedule of 75 mg/m2/day for 42 days followed by 14 days off has been
used in several clinical trials. This schedule provides six weeks of continuous drug exposure
and delivers 50% more drug over two months compared with the standard schedule of five
days every month. However, a phase II trial using extended-dosing temozolomide showed
only a 12.5% response rate [40], which is not different from what would be expected with
standard-dosing of temozolomide or of dacarbazine.
Patients that received oral temozolomide at a starting dosage of 200 mg/m2/d for five days
every 28 days showed median survival time of about eight months, while patients treated with
dacarbazine of about seven months. These results showed that treatment with temozolomide
presented significantly longer survival, nevertheless no major difference in drug safety was
observed. Temozolomide was well tolerated and produced a noncumulative, transient
myelosuppression late in the 28-day cycle. The most common nonhematologic toxicities
observed were mild to moderate nausea and vomiting, which were easily managed. Temozo‐
lomide therapy improved health-related life quality [26].
The most common hematologic side-effect of temozolomide is myelosuppression (similar to
that produced by dacarbazine), particularly neutropenia and thrombocytopenia (dose-limiting
toxicity). In contrast, nausea and vomiting are limited (10–15%), whereas the same side effects
are remarkably severe and very frequent (i.e. of the order of 90%) in patients treated with
dacarbazine. Both drugs can induce headache, fatigue, liver toxicity and constipation [34].
Nevertheless, the development of resistance against the treatment is very common. There
are likely multiple mechanisms of chemotherapy resistance specifically for dacarbazine or
temozolomide,  such as  DNA repair  of  the  adduct  formation (O6-guanine)  with the  O6-
methylguanine-DNA  methyltransferase  [26,41].  Other  mechanisms  of  resistance  include
Bcl-2 overexpression, silencing of apoptotic protease activating factor-1 gene (a key mediator
of  apoptosis),  and  activation  of  proliferative  and  antiapoptotic  signalling  pathways,
including the  mitogen-activated protein  kinase  and phosphoinositide  3-kinase/Akt  path‐
ways [34,35,42-44]. In addition, NF-κB activation of its down-stream target genes (angiogen‐
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esis, adhesion, antiapoptosis, and chemokine growth factors) likely plays a central role in
the  proliferation  and  chemotherapy  resistance  observed  in  melanoma [45-47].  It  is  well
established that  chemotherapy itself  can induce NF-κB activation in  cancer  cells  [46,47].
Any number of these or other biological processes are likely important to chemotherapy
resistance in melanoma.
In an attempt to reduce resistance to chemotherapy in patients with melanoma, new therapies
are introduced including the combination of temozolomide and dacarbazine with other
chemotherapeutic drugs that have similar mechanism of action or act in different ways.
Alternatives used in polychemotherapy in treating melanoma or as monotherapy are the
nitrosoureas such as fotemustine.
2.1.2. Nitrosoureas
The nitrosoureas (carmustine, lomustine, semustine and fotemustine) all have single agent
activity in melanoma because they cross the blood-brain barrier, thus enabling its use in the
treatment of metastatic melanoma. However, at conventional doses, little or no activity was
observed against melanoma brain metastases, and overall response rates were low, with only
a few complete remissions and short response durations [7,48]. Fotemustine is probably the
most active nitrosourea against metastatic melanoma, and especially against cerebral meta‐
stasis; its efficacy has been widely demonstrated through several phase II studies.
In patients without brain metastasis treated with fotemustine, the median time for the
development of brain metastasis was longer as compared to patients treated with dacarbazine
(22.7 months vs. 7.2 months) [49]. It has been widely tested in Europe and has shown overall
response of 20-25%, including 5-8% of complete response rates, and it was the first drug to
show significant efficacy in brain metastases [50,51].
A multicenter trial of monotherapy was undertaken in 153 evaluable French patients, in which
a response rate of 24.2% was obtained. In phase II studies fotemustine was administered
intravenously as a rapid infusion, at a dose of 100 mg/m2 on days 1, 8, 15, then after four to
five weeks every three weeks for maintenance. These studies showed response rates between
16% and 47% in non-visceral metastasis, and long-term survival without metastasis was
reported [50,52,53].
In a phase III clinical trial of fotemustine (100 mg/m2 weekly for three weeks) versus dacarba‐
zine (250 mg/m2/ day for five days every four weeks), the response rate for fotemustine was
15.2% versus 6.8% for dacarbazine [49].
Previous preclinical studies have indicated that fotemustine inhibits enzymes involved in the
ribonucleotide reduction pathway (i.e. DNA synthesis), whereby responding patients ap‐
peared to favour the thioredoxin reductase/thioredoxin electron transfer to ribonucleotide
reductase, whereas non-responders expressed the alternate glutathione reductase/glutaredox‐
in mechanism. The 47% response rate obtained in these studies vs. the 24% reported previously
for fotemustine may reflect variations in enzymes in the ribonucleotide reduction pathway in
different patients. However, the efficacy of fotemustine against advanced melanoma warrants
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more extensive trials of this drug, especially because the quality of life of the patients during
and after chemotherapy was not severely affected [54].
Fotemustine was well tolerated by the patients, with the only mild side effects being throm‐
bocytopenia, leukocytopenia in 40% patients, and easily controlled nausea/vomiting [55].
2.2. Platinum derivatives
Cisplatin and carboplatin have shown modest activity as single agent therapy in patients with
metastatic melanoma. Cisplatin and carboplatin showed good activity against human mela‐
noma cell line, but during in vivo study it did not improve the response comparing with other
drugs used in monoterapy of melanoma treatment. It has been shown that cisplatin induced
a 15% response rate with a short median duration of three months [8]. Evidence that the activity
of cisplatin may be dose-dependent has come from single institution studies. Cisplatin is also
used as a palliative in selected patients with malignant melanoma and central nervous system
metastases. It was shown that cisplatin can be administered alone via intracarotid infusion in
doses varying from 40 to 75mg/m2, but the response is not satisfactory, as only about 13% of
the patients presented stabilization of the disease [56]. With regard to carboplatin, in a study
on 26 chemotherapy naive metastatic melanoma patients, a response rate of 19% with five
partial responses has been reported, and thrombocytopenia was the dose-limiting toxicity [57].
Oxaliplatin is a platinum analogue, which cytotoxic activity observed in an in vitro assay
appears to be significantly superior to that of carboplatin. Its activity becomes comparatively
closer to that of cisplatin as exposure time increases. Indeed, at a 24 h exposure oxaliplatin
appears to be significantly more active than cisplatin [58]. Preclinical data have confirmed its
non-overlapping spectrum of activity with cisplatin, including acquired and intrinsic platinum
resistant cell lines [59]. In a small phase II trial by Evans et al. (1987) [60], no objective response
was observed from 10 patients who had previously failed to respond to chemotherapy.
2.3. Vinca alkaloids
The vinca alkaloids, especially vindesine and vinblastine, are usually used in melanoma
treatment. A phase II study by Mohammed et al. (2000) [61] with vinorelbine 30mg/m2/week
by intravenous bolus with 21 patients no complete or partial response was observed. The
estimated median progression-free survival was two months, and the estimated median
overall survival was six months. Patients received vinorelbine at a dose of 30 mg/m2 on days
one and eight of a 21-day cycle, on an outpatient basis. Thirteen patients were included in the
study, and received 64 cycles. All patients were assessable for response, toxicity and survival.
The median progression-free survival was 3.3 months and the estimated median overall
survival was 8.1 months. Vinorelbine as a single agent on days one and eight of a 21-day cycle
has a favourable toxicity profile, but seems to have no relevant clinical activity in patients with
metastatic melanoma [62] Vindesine is frequently included in combination regimens for the
treatment of malignant melanoma and head and neck cancer, although its single-agent activity
in these diseases is modest (average of 14 and 12% response rates, respectively) [63]. Similarly,
another study that investigated the usefulness of vindesine monotherapy as salvage therapy
in stage IV melanoma patients who had previously failed to respond to chemotherapies also
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failed; the treatment with vindesine 3mg/m2 given to the patients every two weeks in a median
of three treatments was stopped due to the disease progression. The median survival after
starting vindesine therapy was four months. In this study the authors concluded that vindesine
monotherapy is ineffective in stage IV melanoma patients [64]. A phase II study by Retsas et
al. (1979) [68] showed a 30% rate response in 25 patients’ treatment with vindesine, but with
pronounced side effects. Apart from a low rate response the vinorelbine showed significant
toxicity, including febrile neutropenia, granulocytopenia, leukopenia, asthenia, nausea,
neuropathy, myalgia, dyspnea and fatigue [61].
2.4. Taxol
Preclinical studies indicate that taxanes disturb the cytoskeleton architecture and stabilize
microtubules, causing mitotic arrest [65]. Taxol is a major new antitumor agent with significant
activity against a number of human cancers. Preclinical investigation demonstrated significant
activity against B16 melanoma and against cells derived from melanoma in a human stem cell
assay [66]. Studies in phases II and III have shown that taxol has activity against melanoma,
but the responses were partial with 16.2% rate response and median duration of approximately
five months [67]. Another study with paclitaxel administered at a dose of 100mg/m2 intrave‐
nously on day one each week for six weeks, the median survival was 209 days [68]. In a phase
I trial with paclitaxel administered at 200 to 275 mg/m2 over 24 hours every three weeks, there
were four partial responses observed in the 12 patients enrolled [69]. A phase II trial with
paclitaxel administered at 250 mg/m2 over 24 hours every three weeks in 25 patients resulted
in three partial responses (12%); an additional four patients had durable objective regression
although failing to qualify for partial response [74]. An additional 28 evaluated patients were
studied in a second phase II study with paclitaxel administered at 250 mg/m2 over 24 hours.
Four patients (14%) had objective responses with three complete responses [70]. In another
study phase II clinical trial, patients received paclitaxel at 80 mg/m2 over one hour, weekly for
three weeks, followed by a one-week rest period; the disease status was assessed every other
cycle and the treatment was continued until the patients experienced either disease progres‐
sion or unacceptable toxicity. All patients were considered to be evaluable for toxicity and all
patients were included for response assessment in an intention-to-treat analysis. Patients
received paclitaxel for a median of two cycles. None of the 27 patients showed a response to
treatment; eight patients had stable disease. The median progression-free survival was 1.8
months and the median survival was 7.6 months [76]. A phase II trial achieved with paclitaxel
administered at 90 mg/m2 on days one, five, and nine every three weeks demonstrated a 15.6%
response in 5/32 patients [71].
Docetaxel showed an average response rate of 11.4% in three phase II clinical trials. In an assay
performed by the Enzig group, they administered 100 mg/m2 docetaxel every three weeks to
chemotherapy naive patients. Two out of 35 (6%) of the patients responded with one complete
response. Both these responses lasted longer than two years [65]. In a phase II clinical trial, 38
patients were also treated with 100 mg/m2 docetaxel every three weeks and evaluated after
two cycles; five partial responses were noted in the 30 evaluable patients (17%) [72].
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The most common toxicity of taxois is haematological, mainly related with neutropenia.
Additional toxicities included hypersensitivity reaction and diarrhoea, peripheral neuropathy,
fatigue, fluid retention and oral mucositis [72,73].
2.5. Tamoxifen
In 1976, Fischer and collaborators reported the presence of estrogen receptors on human
melanoma cells derived from metastatic tumors [74]. Following a preliminary report, studies
were performed with tamoxifen in the treatment of melanoma, either as a single agent or more
commonly in combination with other chemotherapeutic agents. In a meta-analysis study it
was demonstrated that tamoxifen does not improve the overall response rate, complete
response rate or survival rate when administered as chemotherapy regimens. The rate
responses ranged from zero to 10% [75]. However, for women 50 years of age or older treated
with tamoxifen alone, a response rate of 25% was observed. Despite these promising results,
a subsequent phase II trial published in 1992 showed a response rate of only 4.9% in post-
menopausal women treated with tamoxifen 40 mg daily (14). In phase II studies the patients
treated with tamoxifen 100 mg/m2 did not show objective response [76,77]. Another study by
Aamdal et al. (1994) [78] reported that the enzyme tyrosinase could mimic estrogen receptors
binding, leading to the possibility that this or other interfering substances could account for
apparent estrogen receptors activity and the failure to correlate this activity with response to
tamoxifen. A remaining controversial question is the inclusion of the antiestrogen in different
active chemotherapy regimens, because clinical investigations on the role of tamoxifen in
single agent of melanoma have produced inconclusive results.
2.6. Immunotherapy
The relationship between melanoma and the immune system has been recognized, spontane‐
ous tumor regression in patients with metastatic melanoma have suggested that immuno‐
therapy might have a greater impact on the outcome of metastatic melanoma than in other
cancers [7]. Immune based treatment using biologic response modifiers, especially interleu‐
kin-2 and interferon-α, which have important roles in both adjuvant therapy and in the
treatment of metastatic melanoma, may became an antimelanoma strategy [7,79]. However,
the landscape for late-stage treatment options has changed recently, with FDA approval in
March 2011 for a new immunotherapy drug ipilimumab for treatment of metastatic melanoma
[80]. The Ipilimumab, a humanized monoclonal antibody against CTLA-4, is actually a unique
way of enhancing patients’ immune response against tumors [81].
2.6.1. Interferon alpha (IFN-α)
Interferons represent a family of glycoproteins with a broad spectrum of effects including
antiviral, immunomodulatory, antiproliferative, prodifferentiating and antiangiogenic [82,83].
Interferon-α (INF-α) has shown antitumor activity in metastatic malignant melanoma, both as
single-agent therapy and in combination with chemotherapeutic agents. As a single agent,
IFN-α yields an objective response rate of approximately 15% of responses with less than 5%
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of complete response rates and median response duration of between six and nine months
with a maximum of 12 months for the best studies [84,85]. Patients that received INF-α
intravenously for one month and 10 MIU/m2 subcutaneously three times per week for 48 weeks
showed a significantly increased overall survival rate, with a median follow-up of 6.9 years
(Kirkwood et al., 1996)
In a controlled trial of two lower doses of IFN-α conducted in patients in observation or in
other regimen of treatment, with an intermediate dose of IFN-α (four weeks with 10 MIU/m2
administered five times per week, followed by 10 MIU/m2 three times per week for one year
or five MIU/m2 three times per week for two years) for 13 or 25 months, intermediate dose
IFN-α did not significantly improve distant metastasis free interval or overall survival
outcomes [28]. Low-dose IFN-α also failed to improve survival outcomes versus observation
alone when patients were treated with three MIU/m2 two times weekly for six months or three
MIU/m2 three times weekly for two or three years [86-88]. Clinical data were recorded by IFN-
α dose: high (20 MIU/m2), intermediate (5–10 MIU/m2), low (3 MIU/m2), and very low (1 MIU/
m2) doses. Groups were also stratified by duration of treatment (6 months, 12–18 months or
24 months). Although there was a statistically significant overall survival benefit for treatment
of patients with IFN-α, this assimilation did not find evidence of a clear difference in overall
survival with different dose levels or duration of the treatments [89]. The mechanism of the
therapeutic effects of IFN-α is not completely known. Additional data from Håkansson et al.
(1998) [95] and Yurkovetsky et al. (2007) [96] revealed significant decreases of serum levels of
immunosuppressive and tumor angiogenic/growth stimulatory factors and increased levels
of antiangiogenic. This study also demonstrated a profile of pro-inflammatory cytokines that
may help to predict response to therapy. A fundamental question has been raised regarding
whether the benefit of IFNs such as immunologic, antiangiogenic, or other antitumor effects
would persist long-term or if it would require prolonged, and perhaps indefinite, exposure to
IFN-α [90]. When using IFN-α in the long term, the tolerability needs to be weighed up. IFN-
α induces acute flu like symptoms and widespread haematological and nonhaematological
organ toxicity, dose-dependent fatigue/anorexia, and neuropsychiatric side effects that may
endanger compliance over the course of several years’ therapy [21].
2.6.2. Interleukin-2 (IL-2)
IL-2, a natural product secreted by CD4+ T lymphocytes, was described as a T cell growth factor,
which plays a central role in immune regulation. However, IL-2 can also modulate immuno‐
logical effects by stimulating HLA-restricted or non-restricted cytotoxic cell, activate natural
killer cells, B lymphocytes, macrophages and induce lymphokine-actived killer cells in vitro
as well as the production of other cytokines [7]. The FDA initially approved IL-2 for the
treatment of patients with metastatic melanoma in 1998. High-doses of IL-2 (600.000-720.000
IU/Kg every eight hours on days 1-5 and 15-19) produce overall response rates in 15-20% of
patients with complete responses in 4-6% [91-93]. In phase II trials in patients with metastatic
melanoma, a high-dose regimen of 600.000 U/Kg IL-2 was administered every eight hours for
up to 14 doses; only 16% presented objective response and a small percentage of patients (5%)
experienced long-term, durable complete response, which has been interpreted as a potential
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cure [84]. However, this therapy has not been shown to improve overall survival in the patient
population and has never been evaluated in a phase III setting [94,95]. In addition, IL-2
treatment-related toxicity is severe, which include hemodynamic toxicity (e.g. hypotension,
edema, weight gain and decreased renal function), respiratory insufficiency, and neurotoxicity
[96,97]. Based on the available data assessing prognostic factors and patient selection, patients
with non-visceral metastases and fewer metastatic sites have a much higher response rate. In
these select patients, high dose IL-2 may be considered for first-line therapy [98].
2.6.3. Ipilimumab a new hope for metastatic melanoma
Stimulation of tumor-expressed Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) with soluble
ligands or agonistic mAb triggers the apoptosis [99,100], as well as inhibition of proliferation
and secretion of angiogenic cytokines [101]. Preclinical studies showed that blocking CTLA-4
results in anti-tumor activity and tumor regression in many mice tumor models (prostate,
breast, lymphoma, melanoma) [102,103]. Two anti-CTLA-4 monoclonal antibodies, generated
by different companies, were tested in clinical trials in metastatic melanoma patients: treme‐
limumab (Pfizer) and ipilimumab/Yervoy (Bristol Myers Squibb), but only the latter was
successful in phase III studies. Based on its ability to prolong survival of previously treated as
well as untreated metastatic melanoma patients [104,105], ipilimumab received European
Union (2010) [106] and FDA (March 2011) approval.
Widely touted as a therapeutic breakthrough, ipilimumab works by enhancing T-cell activity
by modifying the function of the CTLA-4 inhibitory receptor. Ipilimumab is directed against
the CTLA-4 antigen present on the surface of cytotoxic T-lymphocytes. The presence of the
CTLA-4 antigen negatively regulates the activity of T-lymphocytes, ultimately suppressing
the immune response [107]. Evidence for ipilimumab offers hope for patients with a clearly
lethal disease, but also highlights some of the dangers and relative infancy of immunotherapies
in the clinical setting [108].
Blocking the CTLA-4 antigen with ipilimumab will stimulate the patient's own immune
response, which will be helpful in destroying cancerous cells [109]. Ipilimumab has been
studied in more than 2,000 patients with metastatic melanoma and response patterns showing
shrinkage of baseline lesions, a decline of tumor burden with a complete response in few
patients. An objective response rate of above 30% was observed in later stages of clinical trials,
after failing in the initial stages of the treatment, in which the response rate was 10%. The
results of the advanced phase III trials indicate that one third of the patients taking Ipilimumab
will receive long-term survival benefits [104]. Objective response rates combining complete
response and partial response were in the range of 5–20% [104,110]. Disease control rates were
reported averaging 15–30%. In contrast, the two therapies approved by the FDA, high-dose of
IL- 2 and dacarbazine, are both associated with response rates of only 10 to 20% and a small
percentage of complete response. They are not thought to improve overall survival [104]. Two
exciting phase III studies tested the clinical effects of Ipilimumab in advanced metastatic
melanoma patients. In the first, 676 participants from 125 different medical centers, who had
already been given standard treatments, received Ipilimumab or gp100 vaccine separately, or
a combination of both, in a randomized, double-blind manner. Treatment with Ipilimumab
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improved median overall survival rates (10.0 and 10.1 months in the Ipilimumab-treated
groups as compared with 6.4 months in the gp100-only treated group). In the second trial [105],
502 patients who had not previously been treated received either dacarbazine (DTIC, standard
care chemotherapy) or Ipilimumab in combination with dacarbazine in a double-blind,
placebo-controlled manner. In this experiment, Ipilimumab increased overall survival rates
from 9.1 to 11.2 months and 3-year survival from 12.2% to 20.8%. A study of single agent
Ipilimumab with intra-patient dose escalation every 2 cycles of therapy also resulted in an
increased toxicity with no improvement in the response rates [111]. In this study, patients were
initially dosed at 3 mg/kg every three weeks for two doses. If there was no objective response
or higher autoimmune toxicity, the dose was increased to 5 mg/kg for two doses and then to
9 mg/kg for two doses. Five out of 46 patients (11%) achieved an objective clinical response at
the expense of 35% of patients experiencing significant toxicities. The authors concluded that
increasing doses of Ipilimumab to increase autoimmune toxicities did not seem to increase the
antitumor activity [111]. Adverse effects, mainly immune related in the skin and gastro-
intestinal track, were experienced by nearly all patients in the two trials, with about half of the
patients suffering from severe adverse effects in the second trial and several severe immune
effects-related deaths in the first trial. Therefore, these exciting results also demonstrate the
complicity of specifically manipulating immune responses.
3. Multi-drugs combinations
The disappointing results with single agent chemotherapy led to the evaluation of multi-drug
combinations regimens in the 1980s in an effort to improve outcome and enhance response
rates in patients with metastatic disease. The combinations of different chemotherapeutic
drugs)or cytotoxic agents with cytokines occasionally yield substantially higher remission
rates without prolonging overall survival [7,21]. The therapeutic schemes that have become
established for melanoma are listed in Table 2. The toxicity of combined chemotherapeutics
regimes is significantly higher than with monotherapy. Multi-drug combinations can, how‐
ever, be of palliative use in individual cases and can provide effective treatment for tumor
related symptoms. Since regimes are potentially toxic, intensive supportive treatment is crucial
for the patient’s quality of life [7].
Many of the combination regimens tested in melanoma (see Table 2) have combined dacarba‐
zine with immunologic agents (e.g., IFN, IL-2), hormones (e.g., tamoxifen) or novel biologic
agents, each of which individually has shown little single-agent activity. Some of the common
combinations of cytotoxic chemotherapeutic regimens used in melanoma are discussed and
the few phase III randomized trials that have been published are highlighted.
Historically, promising combination regimens like BOLD (bleomycin, vincristine, lomustine
and DTIC) and CVD (cisplatin, vinblastine and DTIC) have induced responses on metastatic
lesions in the liver, bone and brain, commonly unresponsive to DTIC alone, even though they
have failed to have an impact on patient survival. Several other studies have suggested a
significant enhancement of antitumor effect associated with the addition of tamoxifen to
Current Therapies and New Pharmacologic Targets for Metastatic Melanoma
http://dx.doi.org/10.5772/55192
201
various cytotoxic regimens [112]. The other drug combinations have been observed and some
authors recommend the combination of cisplatin, carmustine, dacarbazine and tamoxifen as
reference therapy, even though recently presented results of a randomized phase III trial of
this combination versus dacarbazine alone show no statistical difference in survival between
the two groups. While a survival benefit from dacarbazine based chemotherapy or dacarbazine
alone has never been shown in metastatic melanoma patients and, therefore, the survival has
remained unchanged over the past 30 years, some long term survivors have been reported
after receiving the "Dartmouth regimen" (Dacarbazine /Carmustine /Cisplatin /Tamoxifen)
and/or high doses of IL-2 based regimens, whose role is going to be defined in prospective
randomized phase III trials [112].
Scheme Drugs/dosage Overall response
BHD scheme
BCNU 150 mg/m2 i.v. day 1, only every 2nd cycle/Hydroxyurea
1500 mg/m2 oral days 1-5/Dacarbazine 150 mg/m2 i.v. days
1-5 every 4 weeks
12.7-30.4%
BOLD scheme
Belomycin 15 mg i.v. days 1 + 4/Vincristine 1 mg/m2 i.v days
1+ 5/CCNU 80 mg/m2 p.o day 1/Dacarbazine 200 mg/m2 i.v.
days 1-5 every 4-6 weeks
22-40%
DVP scheme Dacarbazine 250 mg/m
2 i.v. days 1-5/Vindesine 3 mg/m2 i.v
day 1/Cisplatin 100 mg/m2 i.v day 1 every 3-4 weeks 31.4-45%
DVP scheme Dacarbazine 450 mg/m
2 i.v. days 1 + 8/Vindesine 3 mg/m2 i.v
day 1 + 8/Cisplatin 50 mg/m2 i.v day 1 + 8 every 3-4 weeks 24%
CarboTax
scheme
Carboplatin AUC6 i.v day 1, after 4 cycles reduce dose to
AUC5/Paclitaxel 225 mg/m2 i.v. day 1 every 3 weeks 12.1% (second-line)
GemTreo scheme Gemcitabine 1000 mg/m
2 i.v. days1 + 8/Treosulfan 3500
mg/m2 i.v. days 1 + 8 every 4 weeks
33.3% (partial remission and
stable disease)
Carmustine 150 mg/m2 i.v. + Vincristine 2 mg/m2 i.v. on day 1
only 25%
Cisplatin 20 mg/m2/day for 4 days starting on day 2 +
Vinblastine 1.6 mg/m2/day x 5 days + Dacarbazine 800
mg/m2 i.v. on day 1
24%
Tamoxifen 10 mg twice daily by mouth 1 week before
chemotherapy + Carmustine 150 mg/m2 on day 1 +
Dacarbazine 220 mg/m2 i.v. + Cisplatin 25 mg/m2/days 1–3
18.5%
Dacarbazine 250 mg/m2 i.v days 1–4 every 3 weeks +
Detorubicin 120 mg/m2 i.v. every 3 weeks 36%
Carmustine 150 mg/m2 i.v. on day 1 + Cisplatin 25 mg/
m2i.v./day on days 1–3 + Dacarbazine 220 mg/m2 i.v./day on
days 1–3 + Tamoxifen 160 mg orally/day x 7 days prior to
chemotherapy. Treatment cycles repeated every 28 days,
BCNU every 2 cycles
26%
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Scheme Drugs/dosage Overall response
Dacarbazine 2.5 mg/m2 i.v. by means of bolus injection on
days 1–4 every 4 weeks + Corynebacterium parvum 7mg i.m. 1
week before starting DTIC and at 4-week intervals thereafter
27%
Dacarbazine 250 mg/m2 i.v. x 5 days, every 3-weeks +
Tamoxifen 20 mg/m2 orally daily 28%
CCNU 200 mg/m2 once every 6 weeks/Dacarbazine 150
mg/m2 i.v. x 5 days/3 weeks + CCNU 130 mg/m2 1/6 weeks 15%
Dacarbazine 250 mg/m2 i.v./day on days 1–5 + Epirubicin 90
mg/m2 on day 1 every 3 weeks 21%
Vinblastine 6 mg/m2/day i.v. on days 1–2 + 24-h infusion of
Bleomycin 15 units/m2 from days 1–5 + Cisplatin 50 mg/m2 1
h i.v. infusion on day 5. After four courses, vinblastine and
Cisplatin were given alone. Courses repeated on a cycle of 4
weeks
10%
Dacarbazine 100 mg/m2 8 h x 6 days every month/
Carmustine 150 mg/m2 + Vincristine 2 mg/m2 every 30 days 24-29%
Dacarbazine 250 mg/m2/day i.v. x 5 days every 4 weeks +
Vindesine 3 mg/m2/week 25%
Dacarbazine 220 mg/m2 on day 1–3 + Carboplatine AUC 5,
day 1, 21 Days 21.3%
IFN-α 15MU/m2/day i.v. days 1–5 x 3 weeks, then 10MU/m2
s.c. 3x/week + Dacarbazine 200 mg/m2 daily i.v. days 1–5
starting on day 22, every 28 days
21%
Tamoxifen 20 mg/day v.o. starting day 1 + Dacarbazine 200
mg/m2/day i.v. days 1–5 every 28 days 18%
IFN-γ 15MU/m2/day i.v. days 1–5 x 3 weeks, then 10MU/m2
s.c. 3x/week + orally Tamoxifen 20 mg/day starting day 1 +
Dacarbazine 200 mg/m2/day i.v. days 1–5/28 days
19%
Dacarbazine 800 mg/m2 i.v. days 1 and 21 + daily INF-α i.m. 3
MIU at days 1–3, 6 MlU days 4–6, and 9 MIU daily thereafter.
Started concomitantly
28%
Dacarbazine 800 mg/m2 i.v. days 1 and 21 + INF-α i.m. 3MIU 3
x /week. Started concomitantly 23%
Dacarbazine i.v. escalating dose 200 mg/m2, 400 mg/m2, 800
mg/m2/3 weeks; IFN-α s.c. starting at 3 MU/day on days 1–3,
9 MU/day on days 4–70, then 9 MU 3 x /week
21%
BCNU = 1,3-bis(chroethyl)-1-nitrosourea (Carmustine) CCNU = Lomustine
Adapted by Garbe et al. (2008) [21] and Mouawad et al. (2010) [7].
Table 2. Multi-drug combinations and their activity in melanoma.
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The Dartmouth Regimen was described for the first time in 1984 with the treatment of 20
patients with melanoma. This association showed promising results, with high response rates
of 40% to 50% [113,114]. However, another study shows a response rate of 18.5% with this
combination [115]. In another randomized phase II trial, Dartmouth Regimen was compared
with dacarbazine alone in patients with melanoma, wherein 60 patients were randomly
assigned to receive carmustine 150 mg/m2 intravenously on day one, cisplatin 25 mg/m2
intravenously daily on days one to three, dacarbazine 220 mg/m2 intravenously daily on days
one to three, and tamoxifen 160 mg orally daily for seven days. The overall response was 26%,
complete responses were 2.5%, with median progression-free survival and the median survival
four and nine months respectively. These results show that the combination had limited impact
on overall survival when compared with dacarbazine alone, with the additional drawback of
high toxicity [116].
In a multicenter phase III trial, 240 patients with measurable stage IV melanoma were ran‐
domly selected to receive the Dartmouth regimen (dacarbazine 220 mg/m2 and cisplatin 25
mg/m2 on days one to three, carmustine 150 mg/m2 on day one every other cycle and tamoxifen
10 mg orally bid). The treatment was repeated every three weeks. The results showed median
survival time from randomization of seven months; response rate was 18.5% when compared
with dacarbazine alone this treatment was not better [115]. In addition to the low activity, the
Dartmounth Regimen showed high toxicity, mainly bone marrow suppression, nausea,
vomiting and fatigue. Although advanced melanoma is often not curable with systemic
therapy, the considered use of currently available regimens can induce clinically significant
remissions and, possibly, prolong the life of some patients.
Su et al. (2011) [124] evaluated the combination of carmustine (150 mg/m2, on day one every
eight weeks), cisplatin (25 mg/m2, days one to three every four weeks), dacarbazine (220
mg/m2 days one to three every four weeks), tamoxifen (10 mg twice a day) and IL-2 18 Million
International Units in divided doses by subcutaneous injection three times a week for four
weeks. The treatment was repeated for a total of six cycles or until disease progression or
unbearable toxicity. The response rate was 32.5% including 5% with a complete response,
27.5% with a partial response and 17.5% with a stable disease. The median progression-free
survival was 6.2 months and median overall survival was 11.3 months. The toxicity associated
with IL-2 included indurate injection site, fever, chills, itchy skin, bone pain and myalgia and
eosinophilia.
The Dartmouth Regimen was associated with IL-2 and IFN-α. In those patients who received
sequential immunotherapy, each cycle of chemotherapy was followed by outpatient s.c. IL-2
(10 x 106 IU/m2, on days three to five, week four; 5 x 106 IU/m2, on days one, three and five,
week five) and s.c. IFN-α (5 x 106 IU/m2, on day one, week four; on days one, three and five,
week five). The overall response rate of patients treated with the combination of chemotherapy
and IL-2/IFN-α was 34.3% with complete responses (10.9%) and partial responses (23.4%). In
patients treated with chemotherapy only, the overall response rate was 29.9% with complete
responses (13.3%) and partial responses (16.6%). There was no significant difference in median
progression-free survival (zero months vs. four months) and in median overall survival (12
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months vs. 13 months) for combined chemoimmunotherapy and for chemotherapy, respec‐
tively [117].
A prospective randomized phase III clinical trial was performed to assess whether the addition
of tamoxifen to the Dartmounth Regimen would ameliorate the responses. The median
survival observed was 6.9 months, but the progression-free survival as well as the overall
survival was not different from the treatment with Dartmounth Regimen alone [118].
Other  chemotherapeutic  agents  have  also  been  combined  with  tamoxifen  for  the  treat‐
ment  of  metastatic  melanoma.  Bajetta  et  al.  (1993)  [119]  treated  two groups  of  patients
sequentially; the first group received carboplatin and cytarabine alone and for the second
group, tamoxifen 40 mg was added daily throughout the cycle. Of 21 evaluable patients
in the first group, 19% responded. In contrast, 8% of patients responded in the tamoxifen-
treated group. All patients had received prior chemotherapy and/or immunotherapy. In an
attempt to confirm synergism between tamoxifen and cisplatin and to overcome clinical‐
ly established cisplatin resistance, McClay et al. (1995) [120] treated 24 metastatic melano‐
ma patients with cisplatin 100 mg/m2 every three weeks; 13% of patients responded. Those
who failed to respond clinically (cisplatin resistant) were then treated with the same dose
of cisplatin plus tamoxifen 160 mg on day one, followed by 20 mg daily throughout the
three-week cycle.  In 19 assessable patients,  16% achieved a complete response or partial
response as conventionally defined; however, when the authors included mixed respons‐
es, the overall response rate (32%) was statistically significantly. In a phase I study, McClay
et  al.  (1995)  [120]  treated successive groups of  patients  with escalating doses of  tamoxi‐
fen and weekly cisplatin 80 mg/m2.  Patients received up to 320 mg/m2  at the time of the
report and none of the patients responded at doses less than 240 mg/m2.
Studies have combined chemotherapy, immunomodulators and tamoxifen. Antoine et al.
(1995) [121] added tamoxifen to a regimen of cisplatin, IL-2, and IFN-γ. The response rate with
tamoxifen (41%) was lower than the response rate observed without tamoxifen (54%). Rixe et
al. (1994) [122] treated 91 patients with high-dose cisplatin, IL-2, IFN-α and tamoxifen. The
trial was stopped prematurely due to an increased frequency of sepsis and because the
response rates were similar to those observed in historical controls that did not receive
tamoxifen.
Fierro et al. (1993) [123] treated 32 patients with a combination including carmustine, cisplatin,
dacarbazine and tamoxifen, which showed an overall response rate of 47%, complete response
of 16%, partial response of 31% and median survival of 10 months. The pretreatment with INF-
α did not modify the survival or the response rate.
In a phase II trial with a high dose of tamoxifen and cisplatin administered weekly were used;
tamoxifen was started on day one with a dose of 240 mg/day. Cisplatin (80 mg/m2) was started
on day two and repeated weekly for a total of three weeks. During week four, the patient was
not treated with cisplatin but was evaluated for response. If disease stabilization or regression
was documented, the patient received a second three-week cycle of cisplatin and was then re-
evaluated for response. Patients with progressive disease at any evaluation were removed
from the study. In 28 consecutive patients, the overall response rate was 32%. Toxicity was
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primarily nausea and vomiting. While this combination presented activity, the overall
response rate was not significantly better that that observed with the original Dartmouth
regimen and besides, the toxicity is substantial [128].
The cisplatin, vinblastine and bleomycin were combined in the treatment of 51 patients with
metastatic melanoma; among these patients only 22% had complete or partial response.
However, the response durations were brief and the toxicity was substantial. The authors
concluded that such a combination was not sufficiently beneficial to warrant its use in
metastatic melanoma [132] Bajetta et al. (1982) [133] treated 22 patients with metastatic
melanoma with vinblastine, bleomycin and cisplatin. In this study, the survival rate was 10
months and the results showed that this combination did not exceed the treatment with
dacarbazine. Nathanson et al. (1981) [134] also studied this combination and the patients
showed a median duration of response of 26 weeks associated with significant toxicity, marrow
suppressive, gastrointestinal, pulmonary and mucocutaneous.
The BOLD scheme (bleomycin, vincristine, lomustine plus dacarbazine) included bleomy‐
cin at 7.5 units subcutaneously in the first course and 15 units in subsequent courses on
days one and four; vincristine at 1mg/m2  intravenously on days one and five; lomustine
at 80 mg/m2  on day one and dacarbazine 200 mg/m2  intravenously on days one through
five.  These  treatments  showed  9%  complete  response,  31%  partial  response  and  17%
stabilization of disease and overall  median survival of 31 weeks. The authors concluded
that  the  BOLD scheme was  an  effective  alternative  treatment  for  metastatic  melanoma,
because the overall toxicity was moderate [135]. Several other works that used the BOLD
scheme in combination with IFN-α showed better results with response rates from 13 to
24%, which is not significant when compared with the treatment with the BOLD scheme
alone, but patients with soft tissue or lung metastases may achieve more complete response
[124].  Another  study  reported  the  treatment  of  twenty-two  patients  with  metastatic
melanoma with the BOLD scheme every four weeks, together with IFN-α 3 x 106 IU daily
for six weeks, followed by 6 x 106 IU three times per week. This treatment showed median
progression-free  survival  of  four  months  and  median  overall  survival  of  12  months,
associated with moderate toxicity [137]. A similar scheme was used in a study reported by
Atzpodien et al. (2002) [125], in which the median progression-free survival was 1.9 months
and  overall  survival  10.6  months,  but  the  scheme showed more  toxicity  in  13% of  the
patients (alopecia and neurotoxicity). The regimen of BOLD plus interferon is active in the
treatment of metastatic uveal melanoma. The precise role of the regimen has to be defined
in light  of  its  toxicity,  particularly  the unpredictable  pulmonary toxicity.  The pattern of
occurrence of these pulmonary events is most consistent with either an acquired hypersen‐
sitivity  reaction,  or  a  cumulative  toxic  effect  from two or  more  agents.  Patients  consid‐
ered for  treatment  with  this  regimen must  be  judiciously  selected.  Those  with  no  clear
contraindications  may benefit  from a trial  of  this  regimen,  but  they must  be  monitored
closely.
Another regimen that has shown good results was the combination of bleomycin 15 mg
administered subcutaneously on days one and four, vindesine 3 mg/m2 administered intra‐
venously on days one and five and lomustine 80 mg/m2 orally on day one and dacarbazine
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200 mg/m2 intravenously on days one through five in a phase III study. This combined response
rate of 45% is considerably better than that seen in single- or dual-agent chemotherapy. The
toxicity was tolerable. The median survival for all treated patients was 43 weeks, and the
median follow-up time was now 63 weeks [139]. Stables et al. (1992) [140] evaluated the
treatment of 72 patients with melanoma with a regime combination including bleomycin,
vindesine, lomustine and dacarbazine. This study showed a complete response in 17.6% of the
patients, partial response in 14.7% of the patients and overall median survival of 38 weeks.
These results are comparable with other combinations of chemotherapy regimens, which have
not yet been supplanted by the newer biological therapies.
Based  on  the  independent  activity  of  cisplatin,  vinblastine,  and  dacarbazine  (CVD),  a
combination of these agents was used in the treatment of patients with advanced melano‐
ma.  Different  doses are used in this  treatment  scheme,  but  the most  common combina‐
tion is vinblastine in a dose of 1.6 mg/m2/d for five days, dacarbazine in a dose of 800 mg/
m2 intravenously on day one, and cisplatin in a dose of 20 mg/m2/d for four days starting
on day two of chemotherapy or, 3-week cycles of cisplatin 20 mg/m2/day x 4; vinblastine
2 mg/m2/day x 4, and dacarbazine 800 mg/m2 on day one [141]. In a phase II trial with 50
evaluable patients, a response rate of 40% was achieved with an estimated 1-year surviv‐
al  of  50% [141].  In  a  randomized  trial  using  biochemotherapy,  in  which  CVD was  the
control arm, the same investigators reported that CVD showed an objective response rate
of 27% and an estimated 1-year survival of approximately 40% [142].  The median dura‐
tion of the response was nine months and the median survival time of the responders was
12  months.  The  treatment  was  associated  with  significant  toxicity  consisting  of  nausea,
vomiting, diarrhoea and partial hair loss. Additionally, neutropenia with a median nadir
granulocyte count of 500/microliters was observed, and significant anaemia required blood
transfusions in a majority of the patients after three to four courses of chemotherapy. The
dose-limiting  toxicity  was  peripheral  neuropathy,  which  required  discontinuation  of
cisplatin after six to eight courses of chemotherapy [141].
Another study used a combination of dacarbazine 250 mg/m2/day one to three, cisplatin 30
mg/m2/day i.v. on days one to three and IFN-α 10 x 106 U/m2/day subcutaneously on days one
to five, and one group received the combination mentioned, plus IL-2 as a continuous i.v.
infusion in a decreasing schedule starting on day 5 with 18 million U/m2 over 6 hours followed
by 18 million U/m2 over 12 hours, 18 million U/m2 over 24 hours, and a maintenance dose of
4.5 million U/m2/24 hours for an additional 72 hours. Cycles were repeated every four weeks
for a maximum of four cycles. This study showed that the combination was not better than the
CVD combination, and was associated with low efficacy and higher toxicity. The authors
concluded that the combination neither conferred a clinically meaningful survival benefit for
most patients with advanced melanoma, nor conferred an increase in rate response or
progression time [94].
Another study has shown results related to the treatment of patients with metastatic melanoma
with six concurrent biochemotherapy dose levels. The doses were programed as follows:
dacarbazine 800 mg/m2 or 1000 mg/m2 (Day 1); cisplatin 25 mg/m2 or 30 mg/m2 (Days 1-4);
vinblastine 1.6 mg/m2 or 1.8 mg/m2 (Days 1-5); interleukin-2 9 million units (MU) per m2 or 12
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MU/m2 as a 24 h continuous infusion (Days 1-4); and interferon-alpha-2b 5 MU/m2, 10
MU/m2, or 15 MU/m2 (Days 1-5) and 5 MU/m2 (Days 7, 9, and 11) administered subcutaneously.
The dose of IFN-α was reduced in some patients because of thrombocytopenia after five days,
and other toxic effects observed included encephalopathy, renal and hepatic dysfunction,
pancreatitis and ileus. This treatment showed a median time to disease progression of 6.9
months, and median survival duration of 12.2 months [143]. In a study reported by Legha et
al. (1996) [90] e treatment with CVD plus IL-2 or IFN-α reached an overall response rate of
60%, although the duration of partial response was short (median eight months), the median
survival of patients receiving sequential biochemotherapy was 13 months compared to nine
months observed in the CVD treated group. The treatment with biochemotherapy was
associated with severe toxicity including intense myelosuppression, infections; IL-2 induced
constitutional toxicity and hypotension. The biochemotherapy regimen produced an apparent
increase in the median survival compared to that observed with the CVD regimen.
In a randomized study, 176 patients received cisplatin and dacarbazine with or without
carmustine every 21 days, or the same regimen followed by low-dose subcutaneous IL-2 for
eight days and IFN-α three times a week, both for six cycles. The regimen without IL-2 and
IFN-α resulted in a median overall survival of 9.5 months and the regimen with IL-2 and IFN-
α of 11.0 months. The regimen with low-dose immunotherapy did not produce a statistically
significant advantage in overall survival, time to progression or overall response when
compared with the regimen without immunotherapy. However, the results were not different
from the treatment with high dose IL-2 [87].
In a phase III study, 326 patients with metastatic melanoma received the treatment consisting
of a combination of dacarbazine (250 mg/m2 intravenously days one to five every four weeks)
and vindesine (3 mg/m2 intravenously day one weekly), with or without the addition of
cisplatin (100 mg/m2 intravenously day one every four weeks). In this study the authors did
not observe a significant difference in overall survival with addition of cisplatin, but the
median time to progression was significantly longer in patients treated with dacarbazine,
vindesine and cisplatin than patients that did not receive cisplatin (4.2 versus 2.2 months
respectively). However, the combination of the three drugs did not change overall survival
but did significantly increase toxicity such as leukopenia, alopecia and nausea/vomiting [144].
Similar treatment was used in a phase II study with forty patients with disseminated malignant
melanoma. In this study, the authors observed a 38% response rate and median response
duration of four months, but the toxicity was intolerable with symptoms such as nephrotox‐
icity, ototoxicity, hypotonia and nausea/vomiting [126].
Fotemustine has also been used in combination with dacarbazine, in patients with metastatic
melanoma. The response rate was 27.2%, confirming the activity of fotemustine. The combi‐
nation of two drugs showed significant toxicity, mainly haematological with leukopenia and
thrombocytopenia. This schedule with sequential dacarbazine and fotemustine had low
activity against metastatic melanoma, and the response rate for cerebral metastases was not
superior to that shown in other studies with single agent fotemustine, however, the treatment
was well tolerated and can be prescribed to outpatients [54].
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Preclinical studies have shown some clinical activity against melanoma. It consisted of a
combination of carboplatin at an area under the curve (AUC) of 7.5 and paclitaxel at 175
mg/m2 over three hours administered to 17 patients [127]. There was a 20% response rate with
three partial responders in the 15 evaluable patients, with a median survival of nine months.
Another phase II study showed results with the administration of paclitaxel either as mono‐
therapy or combined with carboplatin. In the first treatment paclitaxel was administered at a
dose of 100 mg/m2 intravenously on day one each week for six weeks; in the second treatment
paclitaxel was administered at a dose of 80 mg/m2 intravenously followed by carboplatin 200
mg/m2 on day one each week for six weeks. The next cycle was administered after a two-week
intermission. This study showed median survival time of 209 days in patients that received
only paclitaxel, and 218 days for those treated with paclitaxel/carboplatin, with overall
response rates of less than 10% for both treatments [68]. Paclitaxel at a dose of 100 mg/m2 and
carboplatin of 2 AUC was administered on days one, eight and 15 of a 28 day cycle. This
treatment showed 26% partial response and 19% stable disease and a median overall survival
of 7.8 months [128].
Kottschade et al. (2011) [148] conducted a study in which the patients were treated with
paclitaxel 100 mg/m2 and carboplatin AUC six administered on days one, eight and 15 every
28 days. The median number of treatment cycles was four. This treatment showed 25.6%
responses and median overall survival of 11.1 months. In a study conducted by Pflugfelder et
al. (2011) [149], patients received intravenous paclitaxel 225 mg/m2 plus intravenous carbo‐
platin AUC 6 on day one of a 21 day cycle, with a dose reduction after the fourth cycle to
carboplatin AUC five and paclitaxel 175 mg/m2. This study showed median progression-free
survival of 10 weeks and median overall survival of 31 weeks. Response, progression-free, and
overall survival were equivalent in first and second line patients. Sixty patients out of 61 died
after a median follow-up of seven months. This treatment showed, in all studies, severe
toxicities including neutropenia, thrombocytopenia, neurosensory problems, fatigue, nausea
and vomiting [68,127,129].
The development of targeted therapies has provided new options for the management of
patients with advanced melanoma. There has been particular interest in agents that target the
mitogen-activated protein kinase pathway, which controls tumor growth and survival, and
promotes angiogenesis. Recently, sorafenib, an oral multikinase inhibitor has been tested in
combination with carboplatin and paclitaxel. A phase I trial conducted with 38 patients, who
received either 100, 200, or 400 mg of sorafenib twice daily on days 2 to 19 of a 21-day cycle
with carboplatin at AUC 6 and paclitaxel at 225 mg/m2 administered on day one [130]. The
overall response was 10 out of 24 treated patients with one complete response. Another study,
however, showed that the treatment of 270 patients with paclitaxel at 225 mg/m2 and carbo‐
platin at AUC 6 once every three weeks with or without sorafenib at 400 mg twice daily on
days two to 19. There was no difference in progression-free survival, which was the primary
endpoint, or in response rate [131]. The control group (no sorafenib) showed a response rate
of 11% with a median progression-free survival of 17.4 weeks; the median overall survival was
42 weeks. The cohort receiving sorafenib had essentially identical outcomes. The conclusion
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was that the addition of sorafenib to carboplatin/paclitaxel did not improve the response rate
in contrast to the original observations in the phase I trial [130].
Recently, patients were randomly assigned in a two-to-one ratio to carboplatin (AUC, 5) plus
paclitaxel (175 mg/m2) and bevacizumab (15 mg/kg) administered intravenously once every
three weeks. This study showed an overall response rate of 25.5%. The study did not meet the
primary objective of statistically significant improvement in median survival with the addition
of bevacizumab to carboplatin plus paclitaxel. A larger phase III study will be necessary to
determine whether there is any benefit to the addition of bevacizumab to carboplatin plus
paclitaxel in this disease setting [132].
Schmittel et al. (2006) [133] compared the combination of gemcitabine plus treosulfan with
treosulfan alone in patients with metastatic melanoma; the patients received 1000 mg/m2 of
gemcitabine plus 3500 mg/m2 of treosulfan or 3500 mg/m2 of treosulfan on days one and eight,
and in both groups the cycle was repeated on day 29. Median progression-free survival was
three months and two months for patients undergoing the treatment with gemcitabine plus
treosulfan and treosulfan, respectively. In a phase II clinical trial, gemcitabine plus treosulfan
were tested in patients with metastatic melanoma. The patients received 1000 mg/m2 of
gemcitabine and treosulfan at a dose of 2500 or 3000 mg/m2 in group one, and 3500 or 4000
mg/m2 in group two on days one and eight every four weeks. In the group of patients that
were treated with treosulfan in a dose less or equal to 3000 mg/m2, the response rate was not
observed. Among the patients treated with a dose equal to or more than 3500 mg/m2, a 5%
partial remission was observed, with median survival time of nine months [134]. Another
study by Schmittel et al. (2005) [154] combined gemcitabine plus treosulfan and cisplatin, in
which the patients received 30 or 40 mg/m2 of cisplatin, 1000 mg/m2 of gemcitabine and 3000
mg/m2 of treosulfan on days one and eight repeated on day 29; the median overall survival
was 7.7 months, associated with excessive haematological toxicity.
Dacarbazine 250 mg/m2/day was combined with epirubicin 90 mg/m2 on day one every three
weeks. Partial response of 21.1% was observed [135].
Another phase III study of ipilimumab was carried out in patients with previously untreated
metastatic melanoma. In this case, ipilimumab in combination with dacarbazine was compared
with dacarbazine plus placebo, showing improved overall survival with the antibody therapy.
Responses with the combined therapies seemed to be higher than the therapies with a single
agent (17% compared to 5%) [105]. Data from preclinical and clinical studies have shown that
ipilimumab can cause tumor regression in patients with metastatic melanoma with response
rates of 5.8-22%. Phase III trials have demonstrated a benefit to median overall survival in the
first-line setting in combination with dacarbazine versus dacarbazine alone (11.2 versus 9.1
months), and in the second-line setting in combination with glycoprotein 100 peptide vaccine
(gp100) vs. gp100 alone (10.1 versus 6.4 months). The main toxicities of ipilimumab are immune
related, most commonly skin and gastrointestinal troubles. Bowel perforation and treatment-
related deaths have occurred, although prompt use of steroids and other immunosuppressive
agents can minimize these risks [136].
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In phase II study patients with metastatic melanoma received ipilimumab at three mg/kg every
four weeks for four doses, either alone or with up to six-five-day courses of dacarbazine 250
mg/m2/day. The response rate was 14.3% with ipilimumab plus dacarbazine and median
overall survival was 14.3 months [137].
4. News strategies for treatment of metastatic melanoma
4.1. Signalling molecules targeted therapy
One of the most common signalling pathways affected by mutations in melanoma is the RAF/
MEK/ERK pathway, a highly conserved group of proteins that regulate cell growth, division
and death. In melanoma, the most common mutations are in proteins like BRAF, NRAS, HRAS,
and KIT and lead to constitutive activation of the RAF/MEK/ERK pathway, which stimulates
pro-proliferative genes. BRAF, the serine/threonine specific protein kinase, is triggered by
somatic mutations in 50–70% of melanoma cases. A substitution of glutamic acid for valine at
codon 600 (V600E) is the most common BRAF mutation known [138]. Recently, genotype-
selected metastatic melanoma patients with positive BRAF mutation have been submitted to
clinical trials with drabafenib (accelerated dose titration with 12 mg initial dose), an inhibitor
of BRAF kinase, selective for mutations in BRAF. High response rates were achieved in patients
with melanoma brain metastases leading to nine out of ten patients with a size reduction of
brain lesions [139]. A phase III trial comparing drabafenib (150 mg twice daily, orally) with
dacarbazine (1000 mg/m² intravenously every 3 weeks), higher median progression-free
survival was observed in the drabafenib group than those for dacarbazine. However, dose
reduction of drabafenib was needed in 28% of patients due to adverse effects including nausea,
vomiting, fatigue and neutropenia. Dose reduction was also necessary in patients receiving
dacarbazine (17%) [131].
Despite these front line studies that validated BRAF inhibition and genotyping analysis of
BRAF mutational status as a feasible tool in patients undergoing clinical trials with signalling
molecules targeted therapy, side effects remain the most important concern during therapy.
In this field, another BRAF inhibitor, vemurafenib, was compared to dacarbazine, and studies
demonstrated that vemurafenib-treated patients had higher overall survival rate and final
analysis for progression-free survival than those who received dacarbazine. Also, the vemur‐
afenib-treated group had relative reduction of 63% in the risk of death and of 74% in the risk
of either death or disease progression, as compared to dacarbazine. Regarding adverse effects,
18% of patients treated with vemurafenib presented cutaneous squamous-cell carcinoma,
keratoacanthoma, or both [10].
However, after genetic status assessment, Falchook et al. (2012) [140] demonstrated that
trametinib, a reversible selective allosteric inhibitor of MEK1 and MEK2, had a good clinical
activity in patients with melanoma, suggesting that MEK could be a valid therapeutic target
in BRAF-mutant melanoma. Interestingly, patients were free of proliferative skin lesions such
as squamous-cell carcinoma, a common adverse effect associated with BRAF inhibitors,
representing an advantage of trametinib in treating early-stage diseases [140].
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With regard to drug resistance, antiapoptotic proteins of the Bcl-2 family are closely involved
in this process. This group of proteins regulates apoptosis by blocking the release of cyto‐
chrome c and the overexpression of Bcl-2, which has been partially associated with drug
resistance phenomena (Soengas et al., 2003). In this field, antisense Bcl-2 therapy may be an
alternative coadjutant therapy in melanoma clinical trials. In the past, in vitro experimental
transfection of Bcl-2 was performed in both haematological and solid tumor cells, leading to
multidrug resistant phenotype [141] and recently, oblimersen sodium was combined with
dacarbazine in a clinical trial involving 771 patients with advanced melanoma [13]. This new
drug decreased the expression of Bcl-2 protein by increasing the cleavage of Bcl-2 mRNA by
RNase H [142,143].
Another mechanism of tumor resistance is related to the repair process of damaged DNA.
The poly (ADP-ribose) polymerase-1 (PARP) is the nuclear key enzyme of this process and
mediates the recruitment and activation of repair factors in the DNA break leading to base
excision repair [144].  The first phase I clinical trial with inhibitor of PARP was conduct‐
ed with AG014699,  a prodrug of AG014447,  a potent inhibitor of  PARP, combined with
temozolomide in patients with solid tumors and metastatic melanoma. In this clinical trial,
AG014699 was well  tolerated and proved to be highly and selectively toxic to cells  that
underwent DNA repair [145].
Finally, one of the most studied signalling molecules is NF-κB, a pathway that melanoma cells
use to increase survival, proliferation and resistance to apoptosis, leading to progression of
tumor and metastasis appearance [146,147]. One of the first NF-κB inhibitors used in clinical
trials was bortezomib. Combined with temozolomide, a phase I clinical trial was conducted
in order to establish a schedule use of these drugs, define phase II doses and assess the NF-κB
activity in blood. Results demonstrated that bortezomib failed to inhibit NF-κB, and toxicities
including neurotoxicity, fatigue, diarrhoea and rash were reported [18]. Furthermore, two
years later another phase I trial with patients with advanced solid tumors was conducted in
order to establish new maximum tolerated doses for the combination of bortezomib and
temozolomide with inconclusive results [148]. In addition, both groups of authors suggested
that new studies with strong preclinical rationale have to be conducted in order to cover all
the changes undergone at tumor sites [18,148].
4.2. Electrochemotherapy
After years of experience in delivering genes, DNA and drugs into mammalian cells using
electroporation [149,150], a local tumor ablation modality, the electrochemotherapy (ECT) has
been used effectively in the treatment of various solid tumors, particularly melanoma. ECT
combines chemotherapy and electroporation to increase drug uptake into cancer cells [151].
The European Standard Operating Procedures of Electrochemotherapy (ESOPE) was the
largest study reported so far in patients with melanoma [152]. In this huge clinical trial, the
efficacy and safety of ECT were evaluated according to the drug used, route of administration
and types of electrodes for electroporation. The ESOPE project consisted of the administration
of bleomycin (ineffective for systemic conventional therapy), both intravenously (15000
IU/m2) and intratumorally (1000 IU/cm3), followed by eletroportation. Cisplatin was also
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administered in some patients (only intratumorally), because previous reports had not
substantiated the high efficacy of electrochemotherapy using intravenous injection of cisplatin
[153]. Almost 74% of patients had complete response rate achieved on the electrochemotherapy
treated tumor nodules. Furthermore, side effects were minor and acceptable by patients and
showed great advantages regarding cost and effectiveness.
Recently, another approach using ECT, based on the ESOPE study, has been conducted in
patients with cutaneous and subcutaneous melanoma metastases. Bleomycin was also used as
a drug of choice for most cases, and ECT was conducted after intravenous administration of
bleomycin (15 mg/m2). Results demonstrated that 62% of patients had an objective response
rate for all treated metastases. The authors also observed that 23% of patients had complete
response of metastatic nodules and only 8% of patients showed disease progression. Because
ECT was achieved using low doses of bleomycin, no systemic side effects were observed [154].
Regarding disseminated superficial metastasis, Campana et al. (2012) [175] demonstrated that
several ECT cycles on metastases, unsuitable for resection or unresponsive to conventional
chemotherapy, were effective only in patients with few and small metastases on the lower
limb. Besides the restricted response, ECT was well tolerated and side effects were limited.
4.3. Transarterial chemoembolization
In an attempt to manage metastatic melanoma, especially liver metastases, new approaches
have been tested using the dual blood vessels supply of the liver in combination with anti‐
cancer drugs such as irinotecan and cisplatin. This new approach, the so-called transarterial
chemoembolization (TACE), takes therapeutic advantage of the hepatic artery and branches
of the portal vein. By infusing chemotherapeutic agents directly into vessels followed by
infusion of embolic microspheres, localized therapy and the concentration of the drug in tumor
are achieved. In this field, Venturini et al. (2012) [155] enrolled five chemotherapy-naive
patients with liver metastasis of uveal melanoma in an irinotecan-eluting chemoembolization
trial. TACE was successfully achieved and well-tolerated in all five patients. In addition, a
response rate of 80% was achieved in relation to lesion size and remission. Apart from local
pain and one isolated case of cholecystitis, no further side effects were observed.
In a more complex study design including cisplatin, carboplatin, fotemustine or melphalan
infusion followed by polyvinyl alcohol particles for embolization, 11 patients were monitored
for five to 58 months, and 57% of them presented partial response compared to 29% with stable
disease, and 14% presented new lesions detected during the follow up period. Median survival
of all patients was 11.5 months after metastasis diagnosis [156]. In addition, abdominal and
local pain seems to be the most common effect after TACE procedures. Huppert et al. (2010)
[177] reported that pain began 1-4h after embolization and lasted around one to three days,
and that morphine was necessary in some cases.
Transarterial chemoembolization has the advantages of reducing systemic toxicity of drugs
and increasing intratumor effects leading to better results. However, Schusser et al. (2010)
[178] also reported serious side effects after TACE protocol using fotemustin (100 mg/m2) as a
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first choice, followed by cisplatin (50 mg), including splenic infarction, thrombocytopenia and
gastric ulcer; all events required conservative treatment and prolonged hospitalization.
4.4. Adoptive T cells therapy
Immunotherapy has been widely reported as a promising alternative for a variety of malig‐
nancies including melanoma [157]. To divert the majority of the immune cells to react against
tumor has been a huge challenge among physicians. Particularly, adoptive T cells (ATC)
optimally expanded ex-vivo, in theory, could enhance anti-tumor immune response and form
memory protection against recurrence. A well-established expansion of tumor-infiltrating
lymphocytes (TIL) has been carefully used in clinical trials, especially in metastatic melanoma
patients [79,158-160]. Recently, 93 patients with metastatic melanoma were treated with the
ATC transfer of autologous TIL and IL-2 with a median follow-up of 62 months. 22% of patients
showed complete regression and durable complete responses were seen in patients who had
a median of three different organ sites of metastases including lung, liver, adrenal, muscle,
lymphonodes, and skin [161]. However, some limitation was observed in ATC therapy. Joseph
et al. (2011) [184] reported a negative influence in initial TIL outgrowth in samples obtained
from patients who received systemic therapy 30 days before tumor harvest. This data sug‐
gested that parameters like prior systemic chemotherapy should be considered as important
criteria for patients undergoing ATC therapy. The success of autologous TIL derived from
metastatic tumor tissue is dependent on the TIL initial outgrowth and the tumor characteristics,
rate of TIL and parallel systemic chemotherapy, because the latter determines the rate of TIL
harvested [162].
In an attempt to make up for some limitations of ATC therapy, especially those related to
TIL harvested outgrowth and based on the observation that melanoma-reactive TIL could
be generated from only 50% of harvested samples [163],  autologous T cells transduction
with  T-cell  receptors  (TCR)  against  the  antigen NY-ESO-1 was  carried out.  A retroviral
vector  encoding  a  TCR,  which  recognizes  the  peptide  NY-ESO-1,  an  antigen  highly
expressed  in  almost  50%  of  melanoma  metastases,  was  transfected  into  T-cells  of  pa‐
tients, cultured ex-vivo and transferred to patients together with HD IL-2, as a complemen‐
tary therapy. Results from this vanguard clinical trial showed that five of the 11 patients
with  metastatic  melanoma  experienced  an  objective  response  including  two  complete
responses  during  the  follow-up  period  (20  months),  and  2  patients  demonstrated  com‐
plete regressions that persisted after one year.
5. Insights in side effects prevention
It is clear that the cure for malignant melanoma is still a challenge. One can conceive of many
strategies to combat the disease: i) prevention ii) several kinds of therapies, iii) amelioration
of side effects caused by the therapies. In this regard, there is evidence that natural or semi‐
synthetic compounds can feasibly allow for a wide variety of potential drugs to be employed
in a multitarget approach alone and/or in combined therapies.
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Syed and Muktar (2011) [164] summarized some options in a review article about several plant
products for the prevention and treatment of different kinds of cancer, including melanoma.
Among the compounds they mentioned: genistein, epigallocatechin gallate, resveratrol,
curcumin, fisetin, silymarin lupeol, which are able to stop the growth of tumor cells through
their own multitarget drug properties [164]. In the same context, several research groups,
including ours, have studied gallic acid and its ester derivatives [165-168]. It has been shown
that gallic acid and gallates differing only in the number of carbon atoms in the lateral chain
present antitumor properties, whose mechanism of action is also by a multitarget way,
including cell growth and metastasis inhibition, action against the drug efflux, helping to avoid
the development of resistance as well as a selective cytotoxicity
6. Conclusion
Significant advancements have been made in the last few years about melanoma treatment,
including important information on the molecular mechanism of action of the drugs and the
signalling pathways related to the disease. However, the treatment of patients with advanced
melanoma remains unsatisfactory. Single agent or combinations of chemotherapies including
new agents or biologic response modifiers have not resulted in response rates of durable
remissions high enough to affect median survival. The approval by the FDA of ipilimumab in
2011 brought some optimism among the clinicians who treat patients with metastatic mela‐
noma, but this therapy also has its limitations.
Promising sources of alternative molecules for cancer seem to be plants. In general, natural or
semi-synthetic compounds have shown effectiveness not only in the prevention of the disease
and the development of resistance, but also in important antitumoral activities in vitro and in
pre-clinical assays.
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